132 related articles for article (PubMed ID: 11358381)
1. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo.
Schmitt CA; Lowe SW
Blood Cells Mol Dis; 2001; 27(1):206-16. PubMed ID: 11358381
[TBL] [Abstract][Full Text] [Related]
2. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
3. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of chemoresistance in primary murine lymphomas.
Schmitt CA; Rosenthal CT; Lowe SW
Nat Med; 2000 Sep; 6(9):1029-35. PubMed ID: 10973324
[TBL] [Abstract][Full Text] [Related]
5. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
6. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.
Reed JC
Semin Hematol; 1997 Oct; 34(4 Suppl 5):9-19. PubMed ID: 9408956
[TBL] [Abstract][Full Text] [Related]
8. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
9. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
10. Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.
Eaton D; Gilham DE; O'Neill A; Hawkins RE
Gene Ther; 2002 Apr; 9(8):527-35. PubMed ID: 11948378
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins.
Blood A; Edwards CJ; Ishii HH; Pat BK; Bryson G; Sculley TB; Gobe GC
Arch Virol; 2004 Feb; 149(2):289-302. PubMed ID: 14745596
[TBL] [Abstract][Full Text] [Related]
16. An immunophenotypic and molecular study of primary large B-cell lymphoma of bone.
Huebner-Chan D; Fernandes B; Yang G; Lim MS
Mod Pathol; 2001 Oct; 14(10):1000-7. PubMed ID: 11598170
[TBL] [Abstract][Full Text] [Related]
17. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
18. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
